Effect of vitamin D supplementation on sarcopenia in sarcopenic end stage renal disease patients

Effect of cholecalciferol supplementation on sarcopenia in sarcopenic end stage kidney disease patients - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/08/092512

Enrollment

120

Registered

2025-08-06

Start date

Unknown

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N186- End stage renal disease

Interventions

Intervention1: Cholecalciferol supplementation: All sarcopenic end stage kidney patients with vitamin D levels 30-20 ng/ ml (insufficient) and 20 mg/ml(deficienct) will be supplemented with 60,000 in

Eligibility

Inclusion criteria

Inclusion criteria: End stage ren disease patients (ckd5 - dialysis and non dialysis patients)

Exclusion criteria

Exclusion criteria: Age more than 60 years, bedridden patients, patients with malignancy, HIV, tuberculosis, chronic liver disease , pregnant women, already taking vitamin D supplementation for last 3 months before study enrollment

Design outcomes

Primary

Measure	Time frame
To study the effect of cholecalciferol supplementation on sarcopenia in sarcopenic end stage renal disease patientsTimepoint: 3 months and 6 months	—

Secondary

Measure	Time frame
To estimate the prevalence of sarcopenia in end stage kidney disease patients, to determine risk factors like age, gender, diabetes, hypertension, coronary artery disease , different hormonal deficiency or excess associated with sarcopenia in end stage kidney disease patients, to study improvement in quality of life after supplementation of cholecalciferol in sarcopenic end stage kidney disease patientsTimepoint: 0 and 6 months	—

Measure

Time frame

To estimate the prevalence of sarcopenia in end stage kidney disease patients, to determine risk factors like age, gender, diabetes, hypertension, coronary artery disease , different hormonal deficiency or excess associated with sarcopenia in end stage kidney disease patients, to study improvement in quality of life after supplementation of cholecalciferol in sarcopenic end stage kidney disease patientsTimepoint: 0 and 6 months

—

Countries

India

Contacts

Public ContactDr Lalit Pursnani

ABVIMS RML HOSPITAL

drlalitkpursnani@gmail.com9958268930

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026